列线图风险分层预测PSMA PET分期寡复发前列腺癌转移灶定向立体定向放疗反应(PORTAL):国际回顾性队列研究
PORTAL国际回顾性队列研究开发并验证列线图预测寡复发前列腺癌转移灶定向放疗后的无ADT生存。
要点
- 列线图可预测寡复发前列腺癌转移灶定向放疗后1年无ADT生存。
- 独立预测因素包括治疗前PSA、PSA倍增时间、3-5个病灶和远处转移。
- 模型区分度中等,但风险分层能有效区分预后组,可能辅助治疗选择。
核心结论
- 列线图可预测寡复发前列腺癌转移灶定向放疗后的无ADT生存,风险分层有临床意义。
临床怎么用
- 列线图可用于寡复发前列腺癌患者转移灶定向放疗前的风险分层,辅助识别可能从治疗中获益的人群。
局限性
- 个体水平区分度中等,模型预测能力有限。
- 回顾性设计可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Metastasis-directed therapy (MDT) can defer androgen deprivation therapy (ADT) in oligorecurrent prostate cancer, but outcomes vary and there is a paucity of risk stratification tools. We aimed to develop and validate a nomogram to predict ADT-free survival. METHODS: In this international, retrospective cohort study across ten hospitals and academic institutions in Europe (Austria, Italy, Latvia, the Netherlands, Poland, and Portugal), we included men aged 18 years and older with histologically confirmed prostate cancer (all subtypes) previously treated with curative-intent local therapy, who developed metachronous oligorecurrent, hormone-sensitive disease (≤5 prostate-specific membrane antigen [PSMA] PET-detected pelvic nodal or distant metastases or both) and received stereotactic body radiotherapy to all lesions without adjuvant systemic therapy. The primary endpoint was the proportion of patients remaining ADT-free at 1 year of follow-up. Ten clinical predictors were evaluated in a multivariable Cox model with backward elimination. Internal validation with bootstrapping assessed model performance (C-index and calibration), followed by external validation. FINDINGS: A total of 1461 men treated between July 1, 2014, and Dec 31, 2023, were screened, of whom 586 were included in the development cohort (307 [52%] pelvic nodal and 279 [48%] distant metastases); median follow-up was 37 months (IQR 24-58). The external validation cohort (henceforth validation cohort) comprised 131 patients (57 [44%] pelvic nodal, 74 [56%] distant), with a median follow-up 43 months (24-57). ADT-free survival at 1 year was 84·3% (95% CI 81·4-87·3) in the development cohort and 92·8% (88·4-97·4) in the validation cohort. Independent predictors of earlier ADT initiation were higher pre-MDT PSA (hazard ratio 1·05 [95% CI 1·03-1·08]), shorter PSA doubling time (0·97 [0·95-0·98]), three to five lesions (HR 1·74 [1·33-2·28]), and distant metastases (HR 1·45 [1·18-1·78]). Model discrimination was 0·66 (95% CI 0·65-0·68) in the development cohort and 0·65 (95% CI 0·55-0·75) in the external validation cohort. Risk stratification separated patients into three prognostic groups-low risk, intermediate risk, and high risk (p<0·0001). INTERPRETATION: This nomogram predicts ADT-free survival after MDT in oligorecurrent prostate cancer. While individual-level discrimination was modest, risk-group stratification showed meaningful separation, supporting its potential use in treatment selection. FUNDING: None.
引用
- Soeterik TFW, Miszczyk M, Peters M, et al. Nomogram-based risk classification for predicting response to metastasis-directed stereotactic body radiotherapy in PSMA PET-staged oligorecurrent prostate cancer (PORTAL): an international, retrospective cohort study. Lancet Oncol. 2026. PMID: 41713474. doi:10.1016/S1470-2045(25)00717-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。